文献速递肝病

代谢功能障碍相关脂肪性肝炎(MASH)伴纤维化患者肝脏相关事件风险:不同风险分层标准的比较分析

Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
PubMed 文献 · Hepatology · 2023-10-02

该研究纳入1938例经活检证实的MASLD患者,比较高危MASH(MASH伴F2-F4纤维化)与无MASH的F2-F4纤维化患者肝脏相关事件(LRE)风险,并评估LSM≥10 kPa或AGILE 3+>0.67的预测价值。结果显示两类患者LRE风险相似,LSM≥10 kPa或AGILE 3+>0.67可准确识别适合纳入临床试验的MASLD患者。

要点

  • 高危MASH与无MASH的F2-F4纤维化患者5年LRE发生率分别为6.6%和5.1%,风险相似。
  • 以F0-F1无MASH为参照,无MASH的F2-F4纤维化aHR 9.96,高危MASH aHR 10.14。
  • LSM≥10 kPa(aHR 6.31)或AGILE 3+>0.67(aHR 27.45)可独立预测LRE,5年AUC与高危MASH和F2-F4纤维化相似。

核心结论

  • 高危MASH与无MASH的F2-F4纤维化患者LRE风险相似。
  • LSM≥10 kPa或AGILE 3+>0.67可能是识别适合纳入临床试验的MASLD患者的准确选择。

研究设计与样本

  • 研究纳入1938例经活检证实的MASLD连续患者,高危MASH定义为MASH伴F2-F4纤维化。
  • 采用瞬时弹性成像测量LSM,随访记录LRE,使用Cox多因素模型评估关联,并以ROC曲线下面积评估诊断性能。

主要发现

  • F0-F1无MASH、F0-F1伴MASH、无MASH的F2-F4纤维化、高危MASH患者的5年LRE实际发生率分别为0.4%、0.2%、5.1%、6.6%。
  • 以F0-F1无MASH为参照,无MASH的F2-F4纤维化aHR 9.96,高危MASH aHR 10.14,均与LRE相关。
  • 在1074例有LSM数据的患者中,LSM≥10 kPa(aHR 6.31)或AGILE 3+>0.67(aHR 27.45)独立预测LRE。
  • LSM≥10 kPa、AGILE 3+>0.67、高危MASH、F2-F4纤维化的5年AUC分别为0.772、0.818、0.739、0.780。

关键数值与推荐

  • 高危MASH定义为MASH伴F2-F4纤维化。
  • LSM阈值≥8或≥10 kPa,AGILE 3+阈值>0.67。

临床怎么用

  • 作者认为,LSM≥10 kPa或AGILE 3+>0.67可能是识别适合纳入临床试验的MASLD患者的准确选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: International regulatory agencies recommend testing drug therapy for patients with noncirrhotic high-risk metabolic dysfunction-associated steatohepatitis (MASH) because they are at risk of liver-related events (LRE). We aimed to compare the risk of LRE in patients with MASLD stratified for F2-F4 fibrosis and MASH. APPROACH AND RESULTS: Overall, 1938 consecutive patients with biopsy-proven MASLD were enrolled. High-risk MASH was defined as MASH with F2-F4 fibrosis. LSM was measured by transient elastography. LRE were recorded during follow-up. Cox multivariate models were used to assess the association between high-risk MASH or F2-F4 fibrosis without MASH, of LSM (≥8 or ≥10 Kpa), and of AGILE 3+ with LRE. The diagnostic performance for the prediction of LRE was assessed using the area under the receiver operating characteristic curves. The observed 5-year actuarial rate of LRE was 0.4%, 0.2%, 5.1%, and 6.6% in patients with F0-F1 fibrosis without MASH, F0-F1 fibrosis with MASH, F2-F4 fibrosis without MASH, and high-risk MASH, respectively. At multivariate Cox regression analysis using F0-F1 fibrosis without MASH as a reference, both F2-F4 fibrosis without MASH [adjusted HR (aHR) 9.96] and high-risk MASH (aHR 10.14) were associated with LRE. In the 1074 patients with available LSM, LSM ≥ 10 kPa (aHR 6.31) or AGILE 3+ > 0.67 (aHR 27.45) independently predicted the development of LRE and had similarly acceptable 5-year area under the receiver operating characteristic to high-risk MASH and F2-F4 fibrosis (0.772, 0.818, 0.739, and 0.780, respectively). CONCLUSIONS: The risk of LRE is similar in patients with high-risk MASH and with F2-F4 fibrosis without MASH. The use of LSM ≥ 10 kPa or AGILE 3+ > 0.67 could be an accurate option to identify patients with MASLD worthy to be included in clinical trials.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Pennisi G, Enea M, Romero-Gomez M, et al. Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria. Hepatology. 2023. PMID: 37796137. doi:10.1097/HEP.0000000000000616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。